17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma

DISEASE CHARACTERISTICS:

* Histologically confirmed malignant solid tumor OR lymphoma

  * Metastatic or unresectable disease
* Standard curative or palliative measures are not available OR are associated with minimal survival benefit
* No known brain metastases

  * Treated brain metastases allowed provided they have been stable ≥ 6 months without steroids or anti-seizure medications

PATIENT CHARACTERISTICS:

Age

* 18 and over

Performance status

* ECOG 0-2 OR
* Karnofsky 60-100%

Life expectancy

* More than 3 months

Hematopoietic

* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* WBC ≥ 3,000/mm\^3
* Hemoglobin \> 8 g/dL

Hepatic

* AST and ALT ≤ 2 times upper limit of normal
* Bilirubin ≤ 1.5 times normal
* PT and PTT ≤ 1.5 times normal (unless due to the presence of lupus anticoagulant or stable anticoagulation)

Renal

* Creatinine normal OR
* Creatinine clearance ≥ 60 mL/min

Cardiovascular

* No symptomatic congestive heart failure
* No unstable angina pectoris
* No orthostatic hypotension \> grade 2 (requiring more than brief fluid replacement or other therapy OR with physiological consequences)
* No New York Heart Association class III or IV heart failure
* LVEF ≥ 40% by MUGA
* QTc ≤ 450 msec (470 msec for women)
* No congenital long QT syndrome
* No myocardial infarction within the past year
* No active ischemic heart disease within the past year
* No history of uncontrolled dysrhythmias
* No history of serious ventricular arrhythmia (ventricular fibrillation or ventricular tachycardia \> 3 premature ventricular contractions in a row)
* Not requiring antiarrhythmic drugs
* No poorly controlled angina
* No left bundle branch block

Pulmonary

* No uncontrolled symptomatic pulmonary disease, including any of the following:

  * Dyspnea off or on exertion
  * Paroxysmal nocturnal dyspnea
  * Severe chronic obstructive/restrictive pulmonary disease requiring daily chronic medications and oxygen
* Must not meet the Medicare criteria for home oxygen
* No sufficiently compromised pulmonary status as measured by baseline pulmonary function tests and DLCO

Other

* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 2 months after study participation
* No known HIV positivity
* No hyponatremia indicated by sodium \< 130 mmol/L
* No known immunodeficiency syndromes
* No history of allergic reaction attributed to compounds of similar chemical or biological composition to 17-dimethylaminoethylamino-17-demethoxygeldanamycin (geldanamycin or 17-AAG)
* No concurrent uncontrolled illness
* No active or ongoing uncontrolled infection
* No psychiatric illness or social situation that would preclude study compliance

PRIOR CONCURRENT THERAPY:

Biologic therapy

* More than 4 weeks since prior biologic therapy and recovered
* No concurrent prophylactic growth factors

Chemotherapy

* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin, 8 weeks for UCN-01) and recovered

Endocrine therapy

* See Disease Characteristics
* Concurrent hormonal therapy for prostate cancer allowed provided patient has metastatic disease that has progressed despite prior hormonal therapy

Radiotherapy

* More than 4 weeks since prior radiotherapy and recovered
* No prior radiotherapy that included the heart in the field (e.g., mantle radiotherapy)

Surgery

* At least 4 weeks since prior major surgery

Other

* At least 2 weeks since prior participation in a phase 0 study
* Concurrent bisphosphonates for any cancer allowed
* Concurrent preventative doses of aspirin or non-steroidal anti-inflammatory drugs allowed
* No concurrent drugs that may prolong QTc interval
* No concurrent full anticoagulation on a regular basis
* No concurrent prophylactic antiemetics
* No other concurrent investigational agents or therapies
* No other concurrent anticancer agents or therapies